These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16053424)

  • 21. Rilutek should be subsidised.
    Smith W
    Nurs N Z; 2005 Oct; 11(9):4. PubMed ID: 16529266
    [No Abstract]   [Full Text] [Related]  

  • 22. Access to palliative care for people with motor neurone disease in New Zealand: a patient's perspective.
    Williams B
    N Z Med J; 2005 Oct; 118(1224):U1711. PubMed ID: 16258583
    [No Abstract]   [Full Text] [Related]  

  • 23. Minocycline in amyotrophic lateral sclerosis: a pilot study.
    Pontieri FE; Ricci A; Pellicano C; Benincasa D; Buttarelli FR
    Neurol Sci; 2005 Oct; 26(4):285-7. PubMed ID: 16193258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motor neurone disease - caring for the patient in general practice.
    Zoing M; Kiernan M
    Aust Fam Physician; 2011 Dec; 40(12):962-6. PubMed ID: 22146323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease.
    Ishiyama T; Okada R; Nishibe H; Mitsumoto H; Nakayama C
    Brain Res; 2004 Sep; 1019(1-2):226-36. PubMed ID: 15306257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
    Merims D; Ziv I; Djaldetti R; Melamed E
    Lancet; 1999 May; 353(9166):1764-5. PubMed ID: 10347995
    [No Abstract]   [Full Text] [Related]  

  • 27. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of motor neurone disease.
    Howard RS; Orrell RW
    Postgrad Med J; 2002 Dec; 78(926):736-41. PubMed ID: 12509691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motor neuron disease: systematic reviews of treatment for ALS and SMA.
    Orrell RW
    Br Med Bull; 2010; 93():145-59. PubMed ID: 20015852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment approaches in motor neurone disease.
    Dharmadasa T; Matamala JM; Kiernan MC
    Curr Opin Neurol; 2016 Oct; 29(5):581-91. PubMed ID: 27454577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The metabotropic glutamate receptor subtype 5 antagonist MPEP and the Na+ channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesions.
    Risterucci C; Coccurello R; Banasr M; Stutzmann JM; Amalric M; Nieoullon A
    Neuroscience; 2006; 137(1):211-20. PubMed ID: 16242848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis.
    Vucic S; Lin CS; Cheah BC; Murray J; Menon P; Krishnan AV; Kiernan MC
    Brain; 2013 May; 136(Pt 5):1361-70. PubMed ID: 23616585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ALS/MND prevalence in Sweden estimated by riluzole sales statistics.
    Nygren I; Antonova K; Mattsson P; Askmark H
    Acta Neurol Scand; 2005 Mar; 111(3):180-4. PubMed ID: 15691287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Riluzole.
    Gelinas DF
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Dec; 1 Suppl 4():3-4. PubMed ID: 11466957
    [No Abstract]   [Full Text] [Related]  

  • 35. Riluzole for acute traumatic spinal cord injury: a promising neuroprotective treatment strategy.
    Wilson JR; Fehlings MG
    World Neurosurg; 2014; 81(5-6):825-9. PubMed ID: 23295632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole.
    Sívori M; Rodríguez GE; Pascansky D; Sáenz C; Sica RE
    Medicina (B Aires); 2007; 67(4):326-30. PubMed ID: 17891927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.
    Fehlings MG; Wilson JR; Frankowski RF; Toups EG; Aarabi B; Harrop JS; Shaffrey CI; Harkema SJ; Guest JD; Tator CH; Burau KD; Johnson MW; Grossman RG
    J Neurosurg Spine; 2012 Sep; 17(1 Suppl):151-6. PubMed ID: 22985381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A word of caution in extrapolating the riluzole spinal cord injury protective effects obtained in a rabbit model under ketamine anesthesia.
    Miyamoto TA; Miyamoto KJ
    J Thorac Cardiovasc Surg; 1999 Dec; 118(6):1156-7. PubMed ID: 10596003
    [No Abstract]   [Full Text] [Related]  

  • 40. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
    Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
    Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.